Nichtberger Steven 4

What Happened

• Steven Nichtberger, President & CEO and a director of Cabaletta Bio, purchased 45,000 shares on 2026-01-21 in an open-market/private purchase. The reported weighted-average price was $2.24 per share (range $2.1985–$2.26), for a total transaction value of approximately $100,778. This was a purchase (buy), which investors often view as a potentially bullish signal, though it is not proof of future performance.

Key Details

• Transaction date: 2026-01-21
• Transaction type/code: Purchase (P) — open market or private purchase
• Shares acquired: 45,000
• Price: weighted average $2.24; purchase prices ranged from $2.1985 to $2.26 (see footnote F1)
• Total value: ~$100,778
• Shares owned after transaction: Not specified in the provided filing
• Footnotes: F1 explains the weighted-average price and offers to provide the per-price breakdown on request; F2 states the reporting person disclaims beneficial ownership (the filing is not an admission of beneficial ownership)
• Filing timeliness: Report filed dated 2026-01-21 for a transaction on 2026-01-21 — appears timely

Context

• Insider purchases can signal confidence by executives, but they are only one data point and do not guarantee future stock performance. The F2 disclaimer about beneficial ownership is noteworthy — it indicates the filer disclaims beneficial ownership of these shares per the filing language; investors may want to review the full Form 4 for additional context.